During this period, they evaluate whether an every-other-week (EOW) schedule maintains results without triggering hunger, weight regain, fluctuation in blood glucose levels, or metabolic instability
The guide on why semaglutide might not be working covers additional factors beyond dosing that affect results
Note that there are drugs in development as sub-cutaneous (SC) administration (like current Ozempic, Wegovy, Zepbound, Mounjaro), whilst we wont need to wait to long for the oral versions of these drugs to come out (next 6-12 months)
The absence of a head-to-head randomized trial means the final comparative word isnt in yet
IGF-1 LR3 peptide and Fat Cells IGF-1 LR 3 has been speculated by researchers to potentially boost energy metabolism efficiency by inducing cells to become more sensitive to insulin, while at the same time elevating the fat catabolic rate
Moreover, we did not evaluate the effects of other glycemic indices such as 2-h post-prandial glucose due to the lack of examination of this outcome in clinical trials